<DOC>
	<DOCNO>NCT00015808</DOCNO>
	<brief_summary>This study determine high dose idebonone safely give patient Friedrich 's ataxia , inherit degenerative disease cause loss muscle coordination , speech problem , weakness sensory loss . Enlargement leave ventricle ( large pump chamber heart ) also common disease . In study France Canada , patient Friedrich 's ataxia give idebonone , antioxidant similar dietary supplement coenzyme Q , decrease size leave ventricle . Patients 5 year old Friedrich 's ataxia may eligible study . Pregnant lactate woman may participate . Candidates screen medical history physical examination review genetic study . Patients genetic study offer genetic counseling test confirm rule Friedrich 's ataxia . Participants admit NIH Clinical Center 3 day . They blood urine test heart evaluation , include echocardiogram-a procedure use sound wave produce image heart , electrocardiogram-a study electrical activity heart . When test complete , patient take idebonone capsule . They monitor side effect 72 hour . Blood sample collect intravenous catheter ( flexible plastic tube place vein ) 0.5 , 1 , 2 , 3 , 4 , 6 , 12 , 24 , 48 72 hour drug take determine long take drug eliminate body . Patients return follow-up visit within 1 8 week . Those experienced serious side effect may receive another , high dose drug , least 6 day dos .</brief_summary>
	<brief_title>Safety Study Idebenone Treat Friedreich 's Ataxia</brief_title>
	<detailed_description>Friedreich 's ataxia ( FRDA ) progressive , autosomal recessive , multisystem degenerative disease currently effective treatment . Recent study suggest lipid-soluble antioxidant may prevent progression neurodegeneration lead reversal cardiomyopathy . This phase Ia , unblinded , dose-escalation trial examine toxicity tolerability antioxidant idebenone patient FRDA . Our primary objective determine maximum tolerate single dose idebenone patient FRDA . Our secondary objective document pharmacokinetics single-dose idebenone population . We aim enroll 48 patient divide evenly among three age cohort : child ( age 5-11 ) , adolescent ( age 12-17 ) , adult ( age great equal 18 ) . Each age cohort study independently . Three patient cohort receive one day oral idebenone follow inpatient monitoring 72 hour . If dose-limiting toxicity ( DLT ) observe 72-hour study period , three new patient receive next high dose . If one three patient experience DLT , three new patient receive dose . Within cohort , dose escalate maximum tolerate dose ( MTD ) establish . The MTD define one dose result DLT two patient within cohort . Subsequent completion phase Ia trial , plan refine MTD age group phase Ib trial examine multiple-dose regimen longer study period . We hope follow phase I study double-blinded , placebo-controlled phase II trial evaluate safety estimate efficacy idebenone use cardiac parameter primary endpoint . In addition , currently process validate clinical evaluation scale FRDA hope employ measure neurological parameter secondary endpoint phase II trial .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis FRDA confirm FRDA mutation . Age great equal five year old . No exposure idebenone coenzyme Q10 period least one week prior onset medication phase study . Written , inform consent ( assent , applicable ) . EXCLUSION CRITERIA : History hypersensitivity reaction idebenone coenzyme Q10 . Pregnant lactate woman . All woman childbearing potential must negative serum pregnancy prior medication phase study . Age less five year old . Platelet count , lymphocyte count hemoglobin lower limit normal . Alkaline phosphatase , SGOT , SGPT great 1.5 time upper limit normal . Bilirubin great 1.2 g/dl . Creatinine great 1.5 time upper limit normal . Clinically significant medical disease , judgment investigator , would expose patient undue risk harm prevent patient complete study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Neurodegeneration</keyword>
	<keyword>Anti-Oxidant</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Hereditary</keyword>
	<keyword>Spinocerebellar</keyword>
	<keyword>Friedreich 's Ataxia</keyword>
	<keyword>Friedreich Ataxia</keyword>
	<keyword>FRDA</keyword>
</DOC>